Regeneron Pharmaceuticals Inc (REGN)
937.69
+34.67
(+3.84%)
USD |
NASDAQ |
May 02, 16:00
937.69
0.00 (0.00%)
After-Hours: 20:00
Regeneron Pharmaceuticals Cash from Operations (Quarterly): 1.090B for Dec. 31, 2023
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 1.090B |
September 30, 2023 | 1.114B |
June 30, 2023 | 1.022B |
March 31, 2023 | 1.368B |
December 31, 2022 | 1.720B |
September 30, 2022 | 628.90M |
June 30, 2022 | 564.40M |
March 31, 2022 | 2.102B |
December 31, 2021 | 2.372B |
September 30, 2021 | 3.414B |
June 30, 2021 | 626.70M |
March 31, 2021 | 668.50M |
December 31, 2020 | 1.231B |
September 30, 2020 | -254.30M |
June 30, 2020 | 943.40M |
March 31, 2020 | 698.00M |
December 31, 2019 | 787.40M |
September 30, 2019 | 557.30M |
June 30, 2019 | 188.30M |
March 31, 2019 | 897.00M |
December 31, 2018 | 728.80M |
September 30, 2018 | 452.90M |
June 30, 2018 | 394.60M |
March 31, 2018 | 618.80M |
December 31, 2017 | 566.94M |
Date | Value |
---|---|
September 30, 2017 | 414.83M |
June 30, 2017 | -30.57M |
March 31, 2017 | 355.90M |
December 31, 2016 | 390.38M |
September 30, 2016 | 651.03M |
June 30, 2016 | 399.50M |
March 31, 2016 | 44.99M |
December 31, 2015 | 281.82M |
September 30, 2015 | 892.85M |
June 30, 2015 | 257.83M |
March 31, 2015 | -101.73M |
December 31, 2014 | 198.18M |
September 30, 2014 | 164.32M |
June 30, 2014 | 336.41M |
March 31, 2014 | 53.53M |
December 31, 2013 | 281.73M |
September 30, 2013 | 92.46M |
June 30, 2013 | 128.16M |
March 31, 2013 | 86.25M |
December 31, 2012 | 93.18M |
September 30, 2012 | -2.382M |
June 30, 2012 | -78.38M |
March 31, 2012 | -87.04M |
December 31, 2011 | -50.32M |
September 30, 2011 | -46.74M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-254.30M
Minimum
Sep 2020
3.414B
Maximum
Sep 2021
1.097B
Average
943.40M
Median
Jun 2020
Cash from Operations (Quarterly) Benchmarks
Vertex Pharmaceuticals Inc | 234.60M |
Eli Lilly and Co | 1.166B |
AbbVie Inc | 4.753B |
Bristol-Myers Squibb Co | 2.834B |
Amgen Inc | 538.00M |
Cash from Operations (Quarterly) Related Metrics
Cash from Investing (Quarterly) | -66.20M |
Cash from Financing (Quarterly) | -446.10M |
Free Cash Flow | 3.668B |
Free Cash Flow Per Share (Quarterly) | 6.827 |
Free Cash Flow to Equity (Quarterly) | 775.90M |
Free Cash Flow to Firm (Quarterly) | 776.20M |
Free Cash Flow Yield | 3.44% |